# Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD

> **NCT02642614** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 120 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** BI 1026706
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02642614
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-25
- **Primary completion:** 2016-06-14
- **Final completion:** 2016-06-14
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2019-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02642614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02642614, "Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02642614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*